López-Hernández MA, Pérez-Zúñiga JM, Álvarez-Vera JL, Alvarado-Ibarra M

Language: Spanish
References: 10
Page: 393-398
PDF size: 457.69 Kb.

ABSTRACT

Background: Current treatment of acute leukemia is chemotherapy; the liver toxicity is frequently observed which can avoid chemotherapy programs compliance. Iron overload is directly related to serum ferritin, to prevent organ dysfunction, it is necessary to consider chelation therapy in these patients.
Objective: To evaluate the effect of reduced serum ferritin, administering deferasirox, on levels of AST and ALT, in patients with acute leukemia and receiving chemotherapy.
Material and method: An experimental, prospective, longitudinal and non-random study was performed including patients older than 15 years diagnosed with acute leukemia and managed with a program of intensive chemotherapy, complete remission, with ALT + AST greater than 90 IU/L and serum ferritin greater than 1,000 ng/mL. Patients received deferasirox at doses of 30 mg/kg/day.
Results: After beginning the use of deferasirox, the minimum observation time was 6 months and the maximum at the end of the study, 12 months. There were no notable changes in the numbers of bilirubin, alkaline phosphatase, albumin and creatinine. At the end of the study the mean of units transfused after the initial units was 9. Trend was noted receiving fewer transfusions in patients with acute myeloid leukemia treated with deferasirox.
Conclusions: Deferasirox reduces the number of serum ferritin and influences the decrease of ALT and AST. The decrease in AST, ALT and serum ferritin allowed programs meet time and dose chemotherapy. Deferasirox tolerance was good.

REFERENCES

1. Swerdlow SH, Campo E, Harris NL, et al. World Health Organization classification of tumours 2008;18-30.

2. López-Hernández MA, Alvarado-Ibarra M, Jiménez-Alvarado RM, et al. Adolescentes con leucemia aguda linfoblástica de novo: eficacia y seguridad de un protocolo pediátrico versus uno de adultos. Gac Méd Méx 2008;144:485-489.

3. Halonen P, Mattila J, Suominen P, et al. Iron overload in children who are treated for acute lymphoblastic leukemia estimated by liver siderosis and serum iron parameters. Pediatrics 2003;111:91-96.

4. López SN. Terapia de quelación con hierro. Rev Mex Med Tran 2010;3:S80-S86.

5. Kushner JP, Porter JP, Olivieri NF. Secondary iron overload. Hematology Am Soc Hematol Educ Program, 2001;47-61.

6. Takahiro S, Tomonaga M, Miyazaki Y, et al. Japanese epidemiological survey with consensus statement on Japanese guidelines for treatment of iron overload in bone marrow failure syndromes. Int J Hematol 2008;88:30-35.

7. Sijens PE. Liver iron content determination by magnetic resonance imaging. World J Gastroenterol 2010;16:1587-1597.

8. López-Hernández MA, Álvarez Vera JL. Concentraciones de ferritina en pacientes con enfermedades hematológicas transfundidos con más de tres unidades de glóbulos rojos. Med Int Mex 2011;27:17-22.

9. Lee JW, Yoon S, Shen ZX, et al. Iron chelation therapy with deferasirox in patients with aplastic anemia: a subgroup analysis of 116 patients from the EPIC trial. Blood 2010;116:2448-2454.

10. Cappellini MD, Cohen A, Piga A, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with β-thalassemia. Blood 2006107:3455-3462